公开(公告)号：US08206659B2

公开(公告)日：2012-06-26

申请号：US12483787

申请日：2009-06-12

Applicant: Jack Barger ,  James Sinclair ,  Michael P. Emery

Inventor： Jack Barger ,  James Sinclair ,  Michael P. Emery

IPC: B01D9/00

CPC classification number: B01D3/346 ,  B01D1/14 ,  B01L3/06 ,  B01L3/50853 ,  B01L2200/0678 ,  B01L2300/048 ,  B01L2300/049 ,  B01L2300/0829 ,  G01N2001/4027

Abstract: Methods and devices for controlled evaporation of solvent from a solution are provided. In one embodiment, the device can control evaporation of different solutions comprising solvents of dissimilar volatilities simultaneously. In another embodiment, control over the flow of solvent vapor out of the device is provided by selecting the pressure at an inlet port and an exhaust port of the device. In yet another embodiment, control over the flow of solvent vapor out of the device is provided by selecting the size of a disk flow control orifice positioned between the wells and a vapor removal outlet of the device. In still another embodiment, control over the flow of solvent vapor out of the device is provided by the opening and closing of the vapor removal outlet of the device. In yet a further embodiment, the rate of evaporation of solvent is controlled by controlling the temperature of the solution. The flow rate control mechanisms can be used alone or in any combination to control evaporation of one or more solvents from solutions.

Abstract translation: 提供了从溶液中控制溶剂蒸发的方法和装置。 在一个实施方案中，该装置可以同时控制包含不同挥发性溶剂的不同溶液的蒸发。 在另一个实施例中，通过选择装置的入口和排气口处的压力来提供通过装置流出的溶剂蒸气的控制。 在另一个实施方案中，通过选择位于孔之间的盘流量控制孔和装置的蒸汽除去出口的尺寸来提供从装置出来的溶剂蒸气流的控制。 在另一个实施方案中，通过打开和关闭装置的蒸汽除去出口来提供从装置出来的溶剂蒸气流的控制。 在又一个实施方案中，通过控制溶液的温度来控制溶剂的蒸发速率。 流量控制机构可以单独使用或以任何组合使用以控制溶液中的一种或多种溶剂的蒸发。

公开(公告)号：US08200570B2

公开(公告)日：2012-06-12

申请号：US12436259

申请日：2009-05-06

Applicant: James Sinclair ,  James O'Hagan ,  Edward Howorka ,  Neena Jain

Inventor： James Sinclair ,  James O'Hagan ,  Edward Howorka ,  Neena Jain

IPC: G06Q40/00

CPC classification number: G06Q40/04 ,  G06Q30/0601

Abstract: An anonymous trading system includes a prime broker facility that allows a third party to trade on behalf of an institution. A deal is executed between the third party and a counter-party and a further deal is then executed between the third party and the party on whose behalf it has traded. The second deal may be for the same amount as the first deal or may be altered to include the third party's fee for conducting the first deal. Clients of the third party have prices available to them for trades made via the third party which are displayed at their trader terminals. The client sees that a better price is available though the third party than by dealing direct and selects to conduct a deal through the third party.

Abstract translation: 一个匿名的交易系统包括一个主要的经纪人设施，允许第三方代表一个机构进行交易。 第三方与对方之间签订协议，再由第三方与其交易的代理方签订进一步协议。 第二笔交易可能与第一笔交易相同，或可能被更改，以包括第三方进行第一笔交易的费用。 第三方的客户可以通过第三方在其交易终端上显示的交易获得价格。 客户认为，通过第三方可以获得更好的价格，而不是直接交易，并通过第三方进行交易。

公开(公告)号：US20110318357A1

公开(公告)日：2011-12-29

申请号：US13142556

申请日：2010-01-21

Applicant: Alison O'Brien ,  Angela Melton-Celsa ,  Michael Smith ,  James Sinclair

Inventor： Alison O'Brien ,  Angela Melton-Celsa ,  Michael Smith ,  James Sinclair

IPC: A61K39/00 ,  C12N15/11 ,  C12N15/70 ,  A61K38/02 ,  C07K16/12 ,  C12N1/21 ,  A61P31/00 ,  A61P37/04 ,  C12P21/00 ,  C12N5/16 ,  G01N33/566 ,  C07K19/00 ,  A61K39/40

CPC classification number: A61K39/0283 ,  A61K38/00 ,  A61K39/0258 ,  A61K2039/505 ,  C07K7/06 ,  C07K7/08 ,  C07K14/25 ,  C07K16/1232 ,  C07K2317/34 ,  Y02A50/473

Abstract: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.

Abstract translation: 本发明基于11 E1O抗体的Stx2蛋白中的表位的发现。 本发明的特征在于包含非全长Stx2多肽的组合物，其包括11E1O单克隆抗体表位。 本发明还具有产生对Stx2蛋白的11E1O表位特异的抗Stx2抗体的方法。 另外，本发明的特征在于用包含11个E1O的多肽治疗具有或有发展志贺毒素相关疾病（例如，溶血性尿毒症综合征和与大肠杆菌和痢疾杆菌感染相关的疾病）的受试者的方法 表位或使用本发明的方法开发的抗Stx2抗体。 此外，本发明的特征在于使用使用本发明的方法开发的抗体检测样品中的Stx2。

公开(公告)号：US20110203392A1

公开(公告)日：2011-08-25

申请号：US12709414

申请日：2010-02-19

Applicant: James Sinclair ,  B. Albert Griffin ,  Minh Vuong

Inventor： James Sinclair ,  B. Albert Griffin ,  Minh Vuong

IPC: G01N1/20

CPC classification number: G01N9/02 ,  G01N1/20

Abstract: Methods and devices for inline sampling of a bulk material, such as a powder, are provided. The material's bulk density can be determined from samples drawn using methods and devices described herein. One embodiment of a method of sampling a material allows the material to flow through a sampling compartment, closes off the flow of material below the sampling compartment, builds up a column of material through the sampling compartment, shifts the sampling compartment to remove a slice of material in the column, and places the slice of material into a sample container. A device for sampling a material is provided in another embodiment. The device includes an inlet, an outlet aligned with the inlet, and a sample collector. The sample collector can include at least one through hole and be configured to move such that the at least one through hole can be moved into and out of alignment with the inlet and the outlet.

Abstract translation: 提供了散装材料如粉末的在线取样方法和装置。 可以使用本文所述的方法和装置绘制的样品来确定材料的体积密度。 采样材料的方法的一个实施例允许材料流过采样室，封闭采样室下方的材料流，通过采样室建立一列材料，移动采样室以移除一片 柱中的材料，并将切片材料放入样品容器中。 在另一个实施例中提供用于取样材料的装置。 该装置包括入口，与入口对准的出口和样品收集器。 样品收集器可以包括至少一个通孔，并且被配置为移动，使得至少一个通孔可以移动进入和离开与入口和出口对齐。

公开(公告)号：US20090281911A1

公开(公告)日：2009-11-12

申请号：US12436259

申请日：2009-05-06

Applicant: James Sinclair ,  James O'Hagan ,  Edward R. Howorka ,  Jain Neena

Inventor： James Sinclair ,  James O'Hagan ,  Edward R. Howorka ,  Jain Neena

IPC: G06Q30/00

CPC classification number: G06Q40/04 ,  G06Q30/0601

Abstract: An anonymous trading system includes a prime broker facility that allows a third party to trade on behalf of an institution. A deal is executed between the third party and a counter-party and a further deal is then executed between the third party and the party on whose behalf it has traded. The second deal may be for the same amount as the first deal or may be altered to include the third party's fee for conducting the first deal. Clients of the third party have prices available to them for trades made via the third party which are displayed at their trader terminals. The client sees that a better price is available though the third party than by dealing direct and selects to conduct a deal through the third party.

公开(公告)号：US07280871B2

公开(公告)日：2007-10-09

申请号：US10492805

申请日：2002-10-21

Applicant: Glen Macartney Davis ,  Peter James Sinclair ,  Che Fornusek

Inventor： Glen Macartney Davis ,  Peter James Sinclair ,  Che Fornusek

IPC: A61N1/00

CPC classification number: A61N1/36003 ,  A61H1/02 ,  A61H2230/08

Abstract: A control system for controlled exercise controls a functional electrical stimulation (FES) system which applies electrical signals to muscle groups of a user such as a user having a disability; the user exercises on a motor driven exercise machine such that substantially isokinetic exercise during a movement is obtained as the user's body part moves with a motor driven displaceable element of the machine. This element provides resistance to applied displacement load from the user's stimulated muscles. A feedback control system receives signals indicative of the user's performance and a control arrangement controls electrical stimulation to the user's muscles to achieve a desired exercise regime.

Abstract translation: 用于受控运动的控制系统控制将电信号施加到诸如具有残疾的用户的用户的肌肉组的功能性电刺激（FES）系统; 用户在马达驱动的运动器械上进行锻炼，使得当用户的身体部分随着机器的马达驱动的可移动元件移动时，获得运动期间的基本上等速运动。 该元件提供对来自使用者的被刺激的肌肉的施加的位移负荷的抵抗力。 反馈控制系统接收指示用户的性能的信号，并且控制装置控制对用户肌肉的电刺激以实现期望的运动方式。

公开(公告)号：US20060287523A1

公开(公告)日：2006-12-21

申请号：US11391675

申请日：2006-03-29

Applicant: Claude Wischik ,  Janet Rickard ,  Charles Harrington ,  David Horsley ,  John Storey ,  Colin Marshall ,  James Sinclair ,  Han Tan

Inventor： Claude Wischik ,  Janet Rickard ,  Charles Harrington ,  David Horsley ,  John Storey ,  Colin Marshall ,  James Sinclair ,  Han Tan

IPC: C07D279/18

CPC classification number: C09B19/02 ,  C07D279/18

Abstract: This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7-diaminophenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases.

Abstract translation: 本发明一般涉及化学合成和纯化领域，更具体地涉及合成和纯化某些3,7-二氨基吩噻嗪-5-肟化合物（本文中称为“二氨基吩噻嗪鎓化合物”）的方法，包括氯化铁偶氮（MTC）（ 也称为亚甲基蓝）。 在一个实施方案中，该方法包括以下步骤：按顺序：亚硝基化（NOS）; 亚硝酰还原（NR）; 硫代磺酸形成（TSAF）; 氧化偶合（OC）; Cr（VI）还原（CR）; 两性离子中间体（IAPOZI）的分离和纯化; 闭环（RC）; 氯化物盐形成（CSF）; 一种：硫化物处理（ST）; 二甲基二硫代氨基甲酸酯处理（DT）; 碳酸盐处理（CT）; 乙二胺四乙酸处理（EDTAT）; 有机萃取（OE）; 和重结晶（RX）。 本发明还涉及所得的（高纯度）化合物，包含它们的组合物（例如片剂，胶囊）及其在灭活病原体的方法中的用途，以及治疗和诊断方法等，例如对于tau蛋白病 ，阿尔茨海默病（AD），皮肤癌，黑素瘤，病毒性疾病，细菌性疾病或原生动物疾病。

公开(公告)号：US20050221274A1

公开(公告)日：2005-10-06

申请号：US10815176

申请日：2004-03-31

Applicant: Paul Negulescu ,  Alec Harootunian ,  Philip Salzmann ,  Javier Flores ,  James Sinclair ,  Minh Vuong ,  Ashvani Singh ,  Fred VanGoor

Inventor： Paul Negulescu ,  Alec Harootunian ,  Philip Salzmann ,  Javier Flores ,  James Sinclair ,  Minh Vuong ,  Ashvani Singh ,  Fred VanGoor

IPC: B01L3/00 ,  C12M1/34 ,  C12M3/06 ,  G01N33/487 ,  C12Q1/00

CPC classification number: B01L3/5085 ,  B01L3/50255 ,  B01L2300/0645 ,  B01L2300/0829

Abstract: A device for characterizing the biological properties of cells can include a plurality of dual-compartment assay chambers wherein the compartments of each chamber are separated by a cell layer across which ions can flow. The biological properties of the cell layer in the presence or absence of experimental compounds can be determined by measuring an electrical gradient across the layer. A individual dual-compartment chamber of this type may be referred to as an “Ussing chamber.”

Abstract translation: 用于表征细胞的生物学性质的装置可以包括多个双隔室测定室，其中每个室的隔室被离子可以流过的细胞层分开。 在存在或不存在实验化合物的情况下，细胞层的生物学性质可以通过测量该层的电梯度来确定。 这种类型的单室双腔室可以称为“尿素室”。

公开(公告)号：US1386658A

公开(公告)日：1921-08-09

申请号：US41661020

申请日：1920-10-13

Applicant: JAMES SINCLAIR

Inventor： JAMES SINCLAIR

IPC: B65B67/12

CPC classification number: B65B67/12

公开(公告)号：US08969529B2

公开(公告)日：2015-03-03

申请号：US13142556

申请日：2010-01-21

Applicant: Alison O'Brien ,  Angela Melton-Celsa ,  Michael Smith ,  James Sinclair

Inventor： Alison O'Brien ,  Angela Melton-Celsa ,  Michael Smith ,  James Sinclair

IPC: C07K16/12 ,  C12P21/04 ,  C07K14/25 ,  A61K38/00 ,  A61K39/00

CPC classification number: A61K39/0283 ,  A61K38/00 ,  A61K39/0258 ,  A61K2039/505 ,  C07K7/06 ,  C07K7/08 ,  C07K14/25 ,  C07K16/1232 ,  C07K2317/34 ,  Y02A50/473

Abstract: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.

Abstract translation: 本发明基于11 E1O抗体的Stx2蛋白中的表位的发现。 本发明的特征在于包含非全长Stx2多肽的组合物，其包括11E1O单克隆抗体表位。 本发明还具有产生对Stx2蛋白的11E1O表位特异的抗Stx2抗体的方法。 另外，本发明的特征在于用包含11个E1O的多肽治疗具有或有发展志贺毒素相关疾病（例如，溶血性尿毒症综合征和与大肠杆菌和痢疾杆菌感染相关的疾病）的受试者的方法 表位或使用本发明的方法开发的抗Stx2抗体。 此外，本发明的特征在于使用使用本发明的方法开发的抗体检测样品中的Stx2。